Sanofi snaps up inhaled insulin licence


Pharma major Sanofi has struck a licensing deal with US firm Mannkind to develop and commercialise Mannkind’s recently-approved Afrezza inhaled insulin powder for global distribution.

Sanofi will pay $150 million (£89 million) up front, plus up to $775 million in performance milestones. Mannkind will continue to manufacture the product, but Sanofi will cover regulatory and development activities, including expanding manufacturing capacity.


Related Content

Inhaled insulin approved in US

30 June 2014 Business

news image

European committee recommends approval for generic long-acting insulin

Going up in vapour

15 April 2016 Premium contentFeature

news image

As research suggests that e-cigarettes may expose vapers to harmful chemicals, Rebecca Trager finds that governments are catc...

Most Commented

Beyond element 118: the next row of the periodic table

29 January 2016 News and Analysis

news image

A technological leap may be called for to expand the number of elements in existence

New German excellence strategy gets political go-ahead

21 June 2016 News and Analysis

news image

Scheme will provide €500 million to bolster country’s best universities and fund best research